Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines

James L. Mohler; Philip W. Kantoff; Andrew J. Armstrong; Robert R. Bahnson; Michael Cohen; Anthony Victor D'Amico; James A. Eastham; Charles A. Enke; Thomas A. Farrington; Celestia S. Higano; Eric Mark Horwitz; Mark H. Kawachi; Michael Kuettel; Richard J. Lee; Gary R. MacVicar; Arnold W. Malcolm; David Miller; Elizabeth R. Plimack; Julio M. Pow-Sang; Sylvia Richey; Mack Roach; Eric Rohren; Stan Rosenfeld; Eric J. Small; Sandy Srinivas; Cy Stein; Seth A. Strope; Jonathan Tward; Patrick C. Walsh; Dorothy A. Shead; Maria Ho

doi:10.6004/jnccn.2013.0174

Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines

James L. Mohler
, Philip W. Kantoff
, Andrew J. Armstrong
, Robert R. Bahnson
, Michael Cohen
, Anthony Victor D'Amico
, James A. Eastham
, Charles A. Enke
, Thomas A. Farrington
, Celestia S. Higano
, Eric Mark Horwitz
, Mark H. Kawachi
, Michael Kuettel
, Richard J. Lee
, Gary R. MacVicar
, Arnold W. Malcolm
, David Miller
, Elizabeth R. Plimack
, Julio M. Pow-Sang
, Sylvia Richey

Mack Roach, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, Maria Ho

Roswell Park Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center
Duke University
Ohio State University
University of Utah
Memorial Sloan-Kettering Cancer Center
Nebraska Medicine
Prostate Health Education Network (PHEN)
Seattle Cancer Care Alliance
City of Hope National Medical Center
Massachusetts General Hospital Cancer Center
Northwestern University
Vanderbilt University
University of Michigan, Ann Arbor
University of South Florida
University of Tennessee Health Science Center
University of California at San Francisco
University of Texas MD Anderson Cancer Center
National Comprehensive Cancer Network
Stanford University
Washington University St. Louis
Johns Hopkins University

Research output: Contribution to journal › Review article › peer-review

87 Scopus citations

Abstract

The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

Original language	English
Pages (from-to)	1471-1479
Number of pages	9
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	11
Issue number	12
DOIs	https://doi.org/10.6004/jnccn.2013.0174
State	Published - Dec 1 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Bone Neoplasms/secondary
Humans
Male
Neoplasm Staging
Prostatic Neoplasms/diagnosis
Radioisotopes/therapeutic use
Radium/therapeutic use
Recurrence

Access to Document

10.6004/jnccn.2013.0174

Cite this

Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., D'Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Kawachi, M. H., Kuettel, M., Lee, R. J., MacVicar, G. R., Malcolm, A. W., Miller, D., Plimack, E. R., Pow-Sang, J. M., ... Ho, M. (2013). Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 11(12), 1471-1479. https://doi.org/10.6004/jnccn.2013.0174

@article{743ea35b52d54f9b92e5ecdbaa3012b0,

title = "Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.",

keywords = "Bone Neoplasms/secondary, Humans, Male, Neoplasm Staging, Prostatic Neoplasms/diagnosis, Radioisotopes/therapeutic use, Radium/therapeutic use, Recurrence",

author = "Mohler, \{James L.\} and Kantoff, \{Philip W.\} and Armstrong, \{Andrew J.\} and Bahnson, \{Robert R.\} and Michael Cohen and D'Amico, \{Anthony Victor\} and Eastham, \{James A.\} and Enke, \{Charles A.\} and Farrington, \{Thomas A.\} and Higano, \{Celestia S.\} and Horwitz, \{Eric Mark\} and Kawachi, \{Mark H.\} and Michael Kuettel and Lee, \{Richard J.\} and MacVicar, \{Gary R.\} and Malcolm, \{Arnold W.\} and David Miller and Plimack, \{Elizabeth R.\} and Pow-Sang, \{Julio M.\} and Sylvia Richey and Mack Roach and Eric Rohren and Stan Rosenfeld and Small, \{Eric J.\} and Sandy Srinivas and Cy Stein and Strope, \{Seth A.\} and Jonathan Tward and Walsh, \{Patrick C.\} and Shead, \{Dorothy A.\} and Maria Ho",

year = "2013",

month = dec,

day = "1",

doi = "10.6004/jnccn.2013.0174",

language = "English",

volume = "11",

pages = "1471--1479",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "12",

}

Mohler, JL, Kantoff, PW, Armstrong, AJ, Bahnson, RR, Cohen, M, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Kawachi, MH, Kuettel, M, Lee, RJ, MacVicar, GR, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, Richey, S, Roach, M, Rohren, E, Rosenfeld, S, Small, EJ, Srinivas, S, Stein, C, Strope, SA, Tward, J, Walsh, PC, Shead, DA & Ho, M 2013, 'Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 11, no. 12, pp. 1471-1479. https://doi.org/10.6004/jnccn.2013.0174

TY - JOUR

T1 - Prostate cancer, version 1.2014

T2 - Featured updates to the NCCN Guidelines

AU - Mohler, James L.

AU - Kantoff, Philip W.

AU - Armstrong, Andrew J.

AU - Bahnson, Robert R.

AU - Cohen, Michael

AU - D'Amico, Anthony Victor

AU - Eastham, James A.

AU - Enke, Charles A.

AU - Farrington, Thomas A.

AU - Higano, Celestia S.

AU - Horwitz, Eric Mark

AU - Kawachi, Mark H.

AU - Kuettel, Michael

AU - Lee, Richard J.

AU - MacVicar, Gary R.

AU - Malcolm, Arnold W.

AU - Miller, David

AU - Plimack, Elizabeth R.

AU - Pow-Sang, Julio M.

AU - Richey, Sylvia

AU - Roach, Mack

AU - Rohren, Eric

AU - Rosenfeld, Stan

AU - Small, Eric J.

AU - Srinivas, Sandy

AU - Stein, Cy

AU - Strope, Seth A.

AU - Tward, Jonathan

AU - Walsh, Patrick C.

AU - Shead, Dorothy A.

AU - Ho, Maria

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

AB - The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

KW - Bone Neoplasms/secondary

KW - Humans

KW - Male

KW - Neoplasm Staging

KW - Prostatic Neoplasms/diagnosis

KW - Radioisotopes/therapeutic use

KW - Radium/therapeutic use

KW - Recurrence

UR - https://www.scopus.com/pages/publications/84891951693

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000328639000005&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2013.0174

DO - 10.6004/jnccn.2013.0174

M3 - Review article

C2 - 24335682

SN - 1540-1405

VL - 11

SP - 1471

EP - 1479

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 12

ER -

Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this